FVIIa corrects the coagulopathy of fulminant hepatic failure but may be associated with thrombosis: a report of four cases.
Pavese P, Bonadona A, Beaubien J, et al.
Can J Anaesth 2005;52(1):26-29.
Review by
Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis.
Karkouti K, Beattie WS, Wijeysundera DN, et al.
Transfusion 2005;45(1):26-34.
Review by
Successful reversal of deleterious coagulopathy by recombinant factor VIIa.
Haas T, Innerhofer P, Kuhbacher G, Fries D
Anesth Analg 2005;100(1):54-58.
Review by
Hemostatic effect of activated recombinant factor VIIa in Bernard-Soulier syndrome: studies in an in vitro model.
Tonda R, Galan AM, Pino M, Lozano M, Ordinas A, Escolar G
Transfusion 2004;44(12):1790-1791.
Review by
Successful use of one dose of recombinant factor VIIa to control severe bleeding after emergency aortic arch replacement in deep hypothermic circulatory arrest.
Wiesenack C, Arlt M, Liebold A, Schmid FX
J Thorac Cardiovasc Surg 2004;128(6):941-943.
Review by
Factor VIIa for correction of traumatic coagulopathy.
Dutton RP, McCunn M, Hyder M, et al.
J Trauma 2004;57(4):709-719.
Review by
Appropriate use of recombinant factor VIIa: an expanding and unanswered question. [Editorial]
Zimring JC
Transfusion 2004;44(11):1544-1546.
Review by
Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial.
Bosch J, Thabut D, Bendtsen F, et al.
Gastroenterology 2004;127(4):1123-1130.
Review by M. Aldouri
Recombinant activated factor VII in patients with cancer and hemorrhagic disseminated intravascular coagulation.
Sallah S, Husain A, Nguyen NP
Blood Coagul Fibrinolysis 2004;15(7):577-582.
Review by M. Aldouri
Recombinant factor VIIa to control excessive bleeding following surgery for congenital heart disease in pediatric patients.
Tobias JD, Simsic JM, Weinstein S, Schechter W, Kartha V, Michler R
J Intensive Care Med 2004;19(5):270-273.
Review by
The use of recombinant factor VIIa in the treatment of bleeding disorders.
Roberts HR, Monroe DM, White GC
Blood 2004 Aug 24 [Epub ahead of print]
Review by
Transfusion medicine service policies for recombinant factor VIIa administration.
Goodnough LT, Lublin DM, Zhang L, Despotis G, Eby C
Transfusion 2004;44(9):1325-1331.
Review by M. Aldouri
Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.
Mayo A, Misgav M, Kluger Y, et al.
Vox Sang 2004;87:34-40.
Review by
Recombinant factor VIIa for life-threatening bleeding in high-risk cardiac surgery despite full-dose aprotinin.
McIlroy DR, Silvers AJ
Anesth Analg 2004;99:27-30.
Antidotes to haemorrhage: recombinant factor VIIa.
Kessler CM
Best Pract Res Clin Haematol 2004;17:183-197.
Review by M. Aldouri
NATA: Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis
MISSION: Providing a multidisciplinary forum for dialogue between haematologists, transfusion medicine specialists, anaesthesiologists, intensive care and emergency physicians, surgeons, perfusionists, nurses, biomedical scientists and other healthcare professionals.
Sitemap
Contact us
- secretary@nataonline.com
-
NATA
Rue de l’Industrie 24
1040 Bruxelles - VAT: 0781668659